Itsuwa 2023: Decline in Revenue and Profit, Controllers Voluntarily Waiving $690,000 Bonuses

Business by 2FIRSTS, edited by Sophia
Apr.28.2024
Itsuwa 2023: Decline in Revenue and Profit, Controllers Voluntarily Waiving $690,000 Bonuses
Itsuwa's 2023 annual report reveals a significant decline in revenue and profit due to domestic and overseas market challenges.

On April 26th, Itsuwa released its 2023 annual report. During 2023, the company's operating income was 327 million yuan, a decrease of 49.85% compared to the previous year. Net profit attributable to the listed company's shareholders was 22.1272 million yuan, a decrease of 72.75% year-on-year.

 

Itsuwa 2023: Decline in Revenue and Profit, Controllers Voluntarily Waiving $690,000 Bonuses
2023 Annual Report | Image source: Itsuwa

 

The Itsuwa report shows that the company primarily employs an "ODM/OEM production and designated sales" business and sales model, supplying e-cigarettes and their related products to overseas e-cigarette brands for revenue, profit, and cash flow.

 

According to the Itsuwa report, the main reasons for the decline in income are: the impact of e-cigarette policies, the domestic ban on the sale of flavored e-cigarettes other than tobacco flavor, leading to increased competition in overseas markets.

 

The company's main operating gross profit margins in 2021, 2022, and 2023 were 26.20%, 28.56%, and 36.08% respectively. The gross profit margin in 2023 increased, primarily due to the appreciation of the US dollar exchange rate, an increase in the selling price converted to Renminbi compared to the same period last year, and a decrease in prices of key upstream raw materials such as batteries and microphones.

 

It is worth noting that the report highlights that their research and development products include disposable e-cigarettes, pod-system e-cigarettes, with a focus on environmental protection, modularity, and multiple pods.

 

  • The company has developed a biodegradable disposable e-cigarette product in compliance with environmental regulations. The product features a biodegradable shell and a modular design, allowing consumers to return it to designated dealers after use. Dealers can then disassemble the product into biodegradable shells and rechargeable batteries, which can be processed back into disposable e-cigarette products. This product is easy to assemble, has a biodegradable shell, and allows for the reuse of batteries, making it environmentally friendly.
  •  
  • In order to improve the user experience, the company has developed a line of multi-pod products. These pods can be easily interchanged with different flavors and feature a unique rotating structure for convenient and quick switching.

 

Since 2017, the company has actively promoted its own brands of e-cigarettes, such as VAPESOUL and VOOM, targeting different consumer groups with each brand. The sales of own-brand products account for 23.39% of total sales in this period. In 2024, the company plans to continue promoting the sales of its own brand e-cigarettes.

 

Itsuwa mentioned that the two actual controllers of the company, due to the difficulties in business operations in 2023 compared to the previous year (sub-company Shenzhen Wudian Technology Co., Ltd. did not obtain a tobacco monopoly license, resulting in the cessation of e-cigarette business operations, reducing the overall e-cigarette production capacity of the company, and the short-term benefits of its business transformation could not be achieved), have voluntarily waived their personal bonuses for the 2022 fiscal year amounting to 4,999,110.00 yuan in order to alleviate the company's financial pressure.

 

Itsuwa stated that, based on the industry's current situation, regulations are becoming stricter, competition is intensifying, and companies are facing increasing challenges.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU finance ministers failed to reach agreement on tobacco excise reform at the November 9, 2026 Economic and Financial Affairs Council (ECOFIN) meeting in Brussels. The Irish Council presidency's compromise secured support from 26 of the EU's 27 member states, but Malta withheld consent, preventing the Council from reaching a general approach requiring unanimity. The reform would raise minimum taxes on conventional tobacco and bring e-cigarette liquids, heated tobacco and nicotine pouches into a common EU minimum excise framework. Finland and Estonia accepted further concessions during the meeting, while the presidency proposed separating the inclusion of nicotine pouches in the framework from setting their precise minimum tax rates. Another compromise would allow ten qualifying member states until 2036 to meet certain tobacco excise requirements. Ireland intends to continue negotiations in December.
Regulations
Nov.11
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives